527 related articles for article (PubMed ID: 27299434)
1. Secukinumab: A Review in Psoriatic Arthritis.
Shirley M; Scott LJ
Drugs; 2016 Jul; 76(11):1135-45. PubMed ID: 27299434
[TBL] [Abstract][Full Text] [Related]
2. Secukinumab for the treatment of psoriatic arthritis.
Baronaite Hansen R; Kavanaugh A
Expert Rev Clin Immunol; 2016 Oct; 12(10):1027-36. PubMed ID: 27550397
[TBL] [Abstract][Full Text] [Related]
3. Secukinumab for rheumatology: development and its potential place in therapy.
Koenders MI; van den Berg WB
Drug Des Devel Ther; 2016; 10():2069-80. PubMed ID: 27445458
[TBL] [Abstract][Full Text] [Related]
4. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
McInnes IB; Mease PJ; Kirkham B; Kavanaugh A; Ritchlin CT; Rahman P; van der Heijde D; Landewé R; Conaghan PG; Gottlieb AB; Richards H; Pricop L; Ligozio G; Patekar M; Mpofu S;
Lancet; 2015 Sep; 386(9999):1137-46. PubMed ID: 26135703
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab in the Treatment of Psoriasis and Psoriatic Arthritis: A Review of the Literature.
Abrouk M; Gandy J; Nakamura M; Lee K; Brodsky M; Singh R; Zhu H; Farahnik B; Bhutani T; Koo J
Skin Therapy Lett; 2017 Jul; 22(4):1-6. PubMed ID: 28732152
[TBL] [Abstract][Full Text] [Related]
6. Secukinumab: A Review in Psoriatic Arthritis.
Blair HA
Drugs; 2021 Mar; 81(4):483-494. PubMed ID: 33661486
[TBL] [Abstract][Full Text] [Related]
7. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
[TBL] [Abstract][Full Text] [Related]
8. Secukinumab: A Review in Ankylosing Spondylitis.
Blair HA; Dhillon S
Drugs; 2016 Jul; 76(10):1023-30. PubMed ID: 27255593
[TBL] [Abstract][Full Text] [Related]
9. Secukinumab: first global approval.
Sanford M; McKeage K
Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
[TBL] [Abstract][Full Text] [Related]
10. Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis.
Mease PJ; McInnes IB; Kirkham B; Kavanaugh A; Rahman P; van der Heijde D; Landewé R; Nash P; Pricop L; Yuan J; Richards HB; Mpofu S;
N Engl J Med; 2015 Oct; 373(14):1329-39. PubMed ID: 26422723
[TBL] [Abstract][Full Text] [Related]
11. Secukinumab: IL-17A inhibition to treat psoriatic arthritis.
Speeckaert R; van Geel N; Lambert J; Claeys L; Delanghe JR; Speeckaert MM
Drugs Today (Barc); 2016 Nov; 52(11):607-616. PubMed ID: 28112279
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
McInnes IB; Sieper J; Braun J; Emery P; van der Heijde D; Isaacs JD; Dahmen G; Wollenhaupt J; Schulze-Koops H; Kogan J; Ma S; Schumacher MM; Bertolino AP; Hueber W; Tak PP
Ann Rheum Dis; 2014 Feb; 73(2):349-56. PubMed ID: 23361084
[TBL] [Abstract][Full Text] [Related]
14. Secukinumab Improves Physical Function in Subjects With Plaque Psoriasis and Psoriatic Arthritis: Results from Two Randomized, Phase 3 Trials.
Gottlieb AB; Langley RG; Philipp S; Sigurgeirsson B; Blauvelt A; Martin R; Papavassilis C; Mpofu S
J Drugs Dermatol; 2015 Aug; 14(8):821-33. PubMed ID: 26267726
[TBL] [Abstract][Full Text] [Related]
15. Secukinumab: A Review in Ankylosing Spondylitis.
Blair HA
Drugs; 2019 Mar; 79(4):433-443. PubMed ID: 30793255
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab: a review in moderate to severe plaque psoriasis.
Garnock-Jones KP
Am J Clin Dermatol; 2015 Aug; 16(4):323-330. PubMed ID: 26202871
[TBL] [Abstract][Full Text] [Related]
17. Secukinumab (AIN-457) for the treatment of Psoriasis.
Jaleel T; Elmets C; Weinkle A; Kassira S; Elewski B
Expert Rev Clin Pharmacol; 2016; 9(2):187-202. PubMed ID: 26647300
[TBL] [Abstract][Full Text] [Related]
18. Bimekizumab: A Review in Psoriatic Arthritis.
Nie T; Shirley M
Drugs; 2024 May; 84(5):587-598. PubMed ID: 38703349
[TBL] [Abstract][Full Text] [Related]
19. Adalimumab: in psoriatic arthritis.
Simpson D; Scott LJ
Drugs; 2006; 66(11):1487-96; discussion 1497-9. PubMed ID: 16906782
[TBL] [Abstract][Full Text] [Related]
20. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.
Mease P; van der Heijde D; Landewé R; Mpofu S; Rahman P; Tahir H; Singhal A; Boettcher E; Navarra S; Meiser K; Readie A; Pricop L; Abrams K
Ann Rheum Dis; 2018 Jun; 77(6):890-897. PubMed ID: 29550766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
